Analysis of Long-term (Investment) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Abiomed Inc., long-term (investment) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Abiomed Inc. net fixed asset turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Abiomed Inc. total asset turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Abiomed Inc. equity turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
Net Fixed Asset Turnover
Abiomed Inc., net fixed asset turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Revenue | 265,921) | 277,149) | 269,850) | 261,176) | 248,142) | 252,585) | 241,245) | 231,663) | 209,764) | 164,850) | 206,659) | 221,584) | 204,974) | 207,666) | 207,081) | 200,563) | 181,778) | 180,010) | 174,436) | 154,022) | 132,823) | 132,468) | 124,680) | 114,674) | 102,955) | 102,995) | ||||||||
| Property and equipment, net | 195,157) | 198,478) | 202,490) | 196,880) | 197,184) | 198,234) | 197,129) | 179,364) | 175,582) | 170,346) | 164,931) | 162,060) | 157,896) | 151,654) | 145,005) | 138,455) | 134,065) | 127,324) | 117,167) | 107,977) | 97,697) | 92,804) | 87,777) | 60,909) | 50,207) | 25,950) | ||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Net fixed asset turnover1 | 5.50 | 5.32 | 5.10 | 5.10 | 4.94 | 4.72 | 4.30 | 4.53 | 4.57 | 4.68 | 5.10 | 5.19 | 5.20 | 5.26 | 5.31 | 5.32 | 5.15 | 5.04 | 5.07 | 5.04 | 5.17 | 5.12 | 5.07 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.26 | 4.47 | 4.76 | 5.18 | 5.17 | 5.00 | 4.81 | 4.79 | 4.56 | 4.23 | 3.83 | 3.74 | 3.77 | 4.06 | 3.97 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 47.67 | 47.44 | 47.53 | 47.84 | 48.61 | 47.95 | 46.73 | 41.42 | 40.56 | 39.29 | 37.85 | 37.05 | 36.02 | 35.37 | 34.45 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 26.00 | 25.63 | 24.98 | 24.90 | 24.05 | 23.26 | 22.56 | 22.24 | 21.90 | 21.42 | 21.25 | 21.48 | 21.52 | 21.49 | 21.24 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 36.19 | 36.14 | 36.07 | 36.22 | 36.17 | 35.81 | 34.94 | 34.54 | 34.17 | 34.94 | 34.69 | 34.61 | 32.74 | 32.30 | 32.92 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 29.59 | 29.40 | 28.71 | 28.37 | 28.64 | 27.05 | 26.97 | 27.83 | 29.47 | 31.04 | 32.05 | 32.90 | 33.07 | 33.20 | 32.93 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 2.35 | 2.49 | 2.62 | 2.73 | 2.83 | 3.00 | 3.04 | 3.16 | 3.13 | 2.86 | 2.76 | 2.85 | 3.00 | 3.36 | 3.52 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 5.82 | 5.88 | 5.85 | 6.05 | 6.13 | 6.12 | 5.77 | 5.56 | 5.64 | 5.72 | 5.99 | 6.52 | 6.50 | 6.51 | 6.54 | 6.65 | 6.70 | 6.62 | 6.51 | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 10.31 | 10.31 | 10.17 | 10.95 | 11.28 | 10.72 | 9.73 | 7.61 | 6.06 | 4.18 | 4.14 | 4.47 | 3.85 | 3.89 | 8.74 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 31.60 | 31.35 | 31.81 | 33.07 | 32.33 | 32.16 | 31.81 | 31.77 | 30.94 | 30.76 | 29.64 | 30.80 | 30.30 | 29.91 | 27.60 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Net fixed asset turnover
= (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
÷ Property and equipment, net
= (265,921 + 277,149 + 269,850 + 261,176)
÷ 195,157 = 5.50
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Abiomed Inc. net fixed asset turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
Total Asset Turnover
Abiomed Inc., total asset turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Revenue | 265,921) | 277,149) | 269,850) | 261,176) | 248,142) | 252,585) | 241,245) | 231,663) | 209,764) | 164,850) | 206,659) | 221,584) | 204,974) | 207,666) | 207,081) | 200,563) | 181,778) | 180,010) | 174,436) | 154,022) | 132,823) | 132,468) | 124,680) | 114,674) | 102,955) | 102,995) | ||||||||
| Total assets | 1,696,544) | 1,703,636) | 1,673,393) | 1,592,877) | 1,530,034) | 1,458,394) | 1,494,359) | 1,428,434) | 1,327,974) | 1,249,512) | 1,216,462) | 1,196,611) | 1,124,348) | 1,125,060) | 1,054,346) | 957,116) | 887,165) | 812,039) | 786,375) | 719,602) | 694,653) | 652,217) | 550,414) | 500,964) | 474,898) | 429,312) | ||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Total asset turnover1 | 0.63 | 0.62 | 0.62 | 0.63 | 0.64 | 0.64 | 0.57 | 0.57 | 0.60 | 0.64 | 0.69 | 0.70 | 0.73 | 0.71 | 0.73 | 0.77 | 0.78 | 0.79 | 0.76 | 0.76 | 0.73 | 0.73 | 0.81 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.55 | 0.56 | 0.59 | 0.62 | 0.61 | 0.60 | 0.57 | 0.57 | 0.55 | 0.51 | 0.48 | 0.47 | 0.46 | 0.48 | 0.47 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 1.23 | 1.23 | 1.25 | 1.24 | 1.17 | 1.15 | 1.11 | 1.09 | 1.07 | 1.06 | 1.02 | 0.97 | 0.96 | 0.99 | 0.98 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 1.35 | 1.38 | 1.41 | 1.36 | 1.33 | 1.28 | 1.25 | 1.21 | 1.20 | 1.18 | 1.16 | 1.14 | 1.12 | 1.13 | 1.15 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 1.51 | 1.46 | 1.51 | 1.48 | 1.47 | 1.42 | 1.41 | 1.35 | 1.33 | 1.29 | 1.39 | 1.34 | 1.28 | 1.31 | 1.33 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 1.73 | 1.74 | 2.15 | 1.80 | 1.91 | 1.86 | 1.87 | 1.78 | 2.08 | 2.08 | 2.17 | 1.90 | 1.82 | 1.94 | 2.21 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.48 | 0.49 | 0.48 | 0.46 | 0.44 | 0.43 | 0.42 | 0.42 | 0.42 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | 0.46 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.33 | 0.35 | 0.35 | 0.35 | 0.35 | 0.34 | 0.32 | 0.29 | 0.29 | 0.30 | 0.32 | 0.33 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.33 | 0.33 | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 0.78 | 0.71 | 0.76 | 0.90 | 0.87 | 0.80 | 0.69 | 0.59 | 0.47 | 0.31 | 0.25 | 0.21 | 0.18 | 0.23 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 1.23 | 1.18 | 1.31 | 1.29 | 1.32 | 1.33 | 1.34 | 1.30 | 1.29 | 1.27 | 1.30 | 1.31 | 1.28 | 1.29 | 1.38 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Total asset turnover
= (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
÷ Total assets
= (265,921 + 277,149 + 269,850 + 261,176)
÷ 1,696,544 = 0.63
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Abiomed Inc. total asset turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
Equity Turnover
Abiomed Inc., equity turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Revenue | 265,921) | 277,149) | 269,850) | 261,176) | 248,142) | 252,585) | 241,245) | 231,663) | 209,764) | 164,850) | 206,659) | 221,584) | 204,974) | 207,666) | 207,081) | 200,563) | 181,778) | 180,010) | 174,436) | 154,022) | 132,823) | 132,468) | 124,680) | 114,674) | 102,955) | 102,995) | ||||||||
| Stockholders’ equity | 1,539,787) | 1,536,196) | 1,503,326) | 1,432,938) | 1,384,563) | 1,307,522) | 1,329,675) | 1,261,441) | 1,182,409) | 1,101,848) | 1,065,466) | 1,046,863) | 991,457) | 1,002,593) | 936,890) | 851,530) | 792,954) | 723,359) | 689,524) | 632,482) | 604,886) | 567,044) | 452,071) | 417,380) | 398,441) | 377,327) | ||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Equity turnover1 | 0.70 | 0.69 | 0.69 | 0.70 | 0.70 | 0.72 | 0.64 | 0.64 | 0.68 | 0.72 | 0.79 | 0.80 | 0.83 | 0.80 | 0.82 | 0.87 | 0.87 | 0.89 | 0.86 | 0.86 | 0.83 | 0.84 | 0.99 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 1.08 | 1.12 | 1.19 | 1.26 | 1.25 | 1.26 | 1.20 | 1.23 | 1.19 | 1.11 | 1.06 | 1.03 | 1.03 | 1.06 | 1.03 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 4.07 | 4.09 | 4.00 | 3.98 | 3.88 | 3.81 | 3.66 | 3.56 | 3.40 | 3.36 | 3.16 | 3.24 | 3.24 | 3.39 | 3.36 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 4.65 | 4.62 | 4.53 | 4.45 | 4.08 | 4.05 | 3.87 | 3.82 | 3.79 | 3.81 | 3.86 | 3.86 | 3.87 | 4.01 | 4.00 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 4.31 | 4.27 | 4.29 | 4.22 | 4.13 | 3.97 | 3.80 | 3.71 | 3.65 | 3.65 | 3.64 | 3.43 | 3.26 | 3.41 | 3.25 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 5.82 | 5.74 | 6.04 | 5.62 | 5.77 | 5.63 | 5.15 | 4.96 | 5.34 | 5.48 | 5.54 | 4.65 | 4.86 | 5.44 | 5.35 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.56 | 0.57 | 0.56 | 0.53 | 0.50 | 0.49 | 0.48 | 0.48 | 0.48 | 0.45 | 0.45 | 0.47 | 0.50 | 0.54 | 0.54 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.59 | 0.59 | 0.60 | 0.60 | 0.61 | 0.61 | 0.59 | 0.55 | 0.56 | 0.56 | 0.57 | 0.60 | 0.61 | 0.61 | 0.61 | 0.61 | 0.61 | 0.60 | 0.59 | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 1.00 | 0.98 | 0.96 | 1.21 | 1.19 | 1.12 | 0.98 | 0.80 | 0.62 | 0.41 | 0.30 | 0.25 | 0.21 | 0.29 | 0.22 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 4.19 | 4.10 | 4.14 | 4.19 | 4.18 | 4.06 | 3.98 | 3.95 | 3.92 | 3.94 | 3.90 | 3.85 | 3.87 | 4.29 | 4.17 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Equity turnover
= (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
÷ Stockholders’ equity
= (265,921 + 277,149 + 269,850 + 261,176)
÷ 1,539,787 = 0.70
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Abiomed Inc. equity turnover ratio improved from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |